News from the College

  • Class of 2012 Alum Hosts Sensory-Friendly COVID-19 Vaccine Clinics for Children & Adults
    January 14, 2022
    UVM Larner College of Medicine alum Melissa Houser, M.D.'12 founded and partnered with the Vermont Department of Health, Vermont Family Network, Waterbury EMS, and a group of volunteers to create All Brains Belong VT—a nonprofit neuroinclusive primary care and community center offering patient-centered healthcare and inclusively-designed community events. The organization hosted its first sensory-friendly COVID-19 community vaccination clinic in December 2021.
  • Adrianzen Herrera Invested as Early Career Green & Gold Professor of Medicine
    January 13, 2022
    In a ceremony held January 12, 2021, an outstanding early career physician-scientist in the University of Vermont’s Larner College of Medicine, Diego Adrianzen Herrera, M.D., was invested as the inaugural holder of the Early Career Green and Gold Professor of Medicine.
  • Food Security Initiative Buoyed by Generous Gift & Community Partnerships
    December 21, 2021
    A grassroots effort led by Larner College of Medicine alum and Associate Professor of Pediatrics Keith Robinson, M.D.’07, and key partners across the academic medical center and state, has established an invaluable resource to ensure pediatric patients and their families receive the quality and amount of food they need.
  • Sanders Selected as Senior Associate Dean and Executive Clinical Leader
    December 21, 2021
    Jason Sanders, M.D., M.B.A., has been appointed to fill three critical executive leadership roles – senior associate dean for clinical affairs at the UVM Larner College of Medicine, president and CEO of the UVM Health Network Medical Group, and Network executive vice president for clinical affairs. He will begin his work for the College and the Network in February 2022.
  • Larner Welcomes CDC Chief Medical Officer Mitchell Wolfe, M.D.'95
    December 15, 2021
    Mitchell Wolfe, M.D., M.P.H., chief medical officer for the Centers for Disease Control and Prevention (CDC) and a Class of 1995 Larner alum, returned to campus for a personal visit on December 13 for the first time since receiving his medical degree here 26 years ago.
  • UVM Researchers Help Identify Impact of COVID-caused Delays in Breast Cancer Screening
    November 23, 2021
    New research from U.S. Breast Cancer Surveillance Consortium (BCSC) members, including several University of Vermont researchers, found that from March to September 2020, breast biopsies and detected cancers at U.S. BCSC facilities dropped sharply, compared with the same span a year earlier.
  • Potter & Garavan Receive Grant to Study Earliest Brain Development Milestones
    November 17, 2021
    Researchers at the University of Vermont recently received a $5.5 million, five-year grant to participate in the Phase II portion of the HEALthy Brain and Child Development (HBCD) Study, an initiative focused on gathering data on brain development from birth through early childhood.
  • UVM Invests Holcombe as Inaugural J. Walter Juckett Chair in Cancer Research
    November 3, 2021
    With $3 million in support from a longtime major supporter of the University of Vermont Cancer Center, Randall F. Holcombe, M.D., M.B.A., was invested as the inaugural J. Walter Juckett Chair in Cancer Research in the Larner College of Medicine on November 3.
  • Larner Awarded Full 8-Year LCME Accreditation
    November 3, 2021
    The Larner College of Medicine at the University of Vermont has been awarded continued accreditation for a full eight-year term by the Liaison Committee on Medical Education (LCME), the accrediting body for all M.D. degree programs in the U.S. and Canada.
  • UVM Cancer Center Research Leads to First-of-Its-Kind Clinical Trial of Mesothelioma Treatment
    October 26, 2021
    Linked to occupational asbestos exposure, malignant mesothelioma (MM) is an aggressive cancer arising primarily from the outer lining of the lungs with a dismal five-year survival rate of only five to 10 percent. Since 2004, only two therapies have been approved for the treatment of MM, which affects about 3,000 people a year in the United States. Now a promising new therapy for mesothelioma and metastatic cancer, arising from laboratory investigations at the University of Vermont, is about to enter a Phase I clinical trial.